What to include in a compounded sterile prescription

Make the intended prescription easy to understand

A complete request gives the pharmacist a clearer basis for evaluating a compounded sterile prescription. It also gives your practice a record of what was requested and whom to contact when a detail needs clarification. The aim is an accurate conversation, rather than avoiding every follow-up call.

For patient-specific compounding under section 503A, FDA’s guidance addresses the requirement for a valid prescription for an identified individual patient. A general product inquiry, a quote request or a clinic’s preferred formulation list does not serve the same purpose as that prescription.

• Understand patient-specific 503A prescriptions

Prepare a consistent submission checklist

The following is a practical preparation checklist, not an exhaustive statement of legal requirements. Confirm the pharmacy’s accepted submission method and any additional requirements for the patient, drug and prescribing jurisdiction.

• Patient identifiers and contact details sufficient for the pharmacy to match the prescription to the intended person.
• Prescriber identity, practice contact details, prescription date and required signature or electronic authorization.
• Drug or ingredient names, the intended strength or concentration, dosage form and route.
• Clear directions for use, quantity requested and any authorized refills.
• Relevant allergies or ingredient sensitivities and the patient-specific reason for discussing a compounded formulation.
• A direct practice contact for clinical clarification and a separate contact for delivery coordination when appropriate.

Keep concentration, dose and quantity distinct

These fields answer different questions. Concentration describes the amount of drug in a volume of preparation. The prescribed dose and directions describe the intended use. The quantity describes the amount to dispense. Use the pharmacy discussion to resolve unclear wording rather than asking staff to infer the intended formulation.

FDA has reported medication errors involving the way strengths appear on compounded injectable labels, including confusion between an amount per milliliter and the total amount in a container. This is a reason to reconcile the prescription with the proposed preparation and its labeling. If a detail changes, confirm the revised information through the appropriate prescribing workflow.

Account for the prescribing jurisdiction

Florida’s written-prescription statute specifies information such as prescriber name, drug name and strength, quantity, directions, date and signature. It also addresses electronic prescriptions and contains additional provisions. That statute is one reference point; it is not a universal checklist for every medication or state.

Your practice can maintain an internal checklist that points staff to the applicable requirements and separates administrative collection from clinical decisions. Revisit it when the pharmacy identifies a recurring ambiguity, rather than copying an older prescription whose details may no longer fit the current patient or request.

Plan the handoff before the prescription is filled

Ask who will confirm formulation questions, communicate accepted changes, and coordinate patient counseling. Also ask how the patient or clinic will receive the actual storage instructions and beyond-use date. A prescription submission should not imply that a particular formulation, turnaround time or delivery arrangement has already been accepted.

This checklist is educational information, not a prescribing template or medical or legal advice. The prescriber and dispensing pharmacist must resolve the requirements and clinical details of each prescription.

• Plan the clinic–pharmacy onboarding conversation